401 - Effects of nintedanib on dental health of children with interstitial lung disease

Interstitial lung disease is a group of lung conditions that causes scarring or fibrosis of the lung tissues, that can cause the patient to have shortness of breath and coughing. There is currently no approved therapies for the treatment of fibrosing interstitial lung disease in children.  This study was conducted at the UPMC Childrens hospital of Pittsburgh as a double blind, randomized, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with nintedanib of variable duration, in children and adolescents (6-17 years old) with clinically significant fibrosing interstitial lung disease. The main objective of the study is to evaluate dose-exposure and safety of nintedanib in children and adolescents with fibrosing interstitial lung disease. A secondary objective was to monitor potential severe/irreversible effects on dentition and bony changes that may present to maxilla and mandible. The patient presented to the clinic for intraoral/extraoral examination at 12,24,36, and 52 weeks, and panoramic imaging at 0,24, and 52 weeks. Results still pending.